<unk>  in combination with rilpivirine is indicated for the treatment of human immunodeficiency virus type-1 (HIV-1) in adults. The combination injection is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/mL) with their current antiretroviral treatment, and when the virus has not developed resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and integrase strand transfer inhibitors. The tablets are used to check whether a person tolerates the treatment before the injection therapy is started. The two medicines are the first antiretroviral drugs that come in a long-acting injectable formulation.<unk>  (Apretude) is indicated for use in at-risk people weighing at least for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV.
Cabotegravir
Maribavir
Saquinavir
Elvitegravir
Dolutegravir
Fosamprenavir
Fostemsavir
Elbasvir